Last reviewed · How we verify
Levetiracetam IV
Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release.
Levetiracetam reduces neuronal excitability and seizure activity through binding to synaptic vesicle protein SV2A, modulating neurotransmitter release. Used for Epilepsy (adjunctive therapy for partial-onset seizures), Epilepsy (adjunctive therapy for myoclonic seizures), Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures).
At a glance
| Generic name | Levetiracetam IV |
|---|---|
| Sponsor | Ministry of Health and Sports, Myanmar |
| Drug class | Anticonvulsant / Antiepileptic agent |
| Target | SV2A (synaptic vesicle protein 2A) |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
Levetiracetam is a pyrrolidone derivative that binds to the synaptic vesicle protein SV2A in the brain, which regulates the release of neurotransmitters involved in seizure propagation. Unlike traditional anticonvulsants, it does not directly affect sodium or calcium channels, and its exact mechanism remains partially unclear, though SV2A binding is considered the primary molecular interaction. This unique mechanism makes it effective across multiple seizure types with a favorable safety profile.
Approved indications
- Epilepsy (adjunctive therapy for partial-onset seizures)
- Epilepsy (adjunctive therapy for myoclonic seizures)
- Epilepsy (adjunctive therapy for primary generalized tonic-clonic seizures)
Common side effects
- Somnolence
- Asthenia/Fatigue
- Dizziness
- Headache
- Behavioral/mood changes (irritability, aggression)
- Ataxia/Coordination problems
- Infection
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly (PHASE2)
- Levetiracetam Versus Phenobarbitone for the Treatment of Neonatal Seizures in a Tertiary Care Hospital. (NA)
- Study of Antiepileptic Drug in Generalised Convulsive Status Epilepticus (PHASE3)
- Treatment of Seizures in Neonate With HIE (PHASE4)
- Therapy for Children With Advanced Stage Neuroblastoma (PHASE2)
- A Dose Escalation Study of Levetiracetam in the Treatment of Neonatal Seizures (PHASE2)
- Prevention of Epileptic Seizures in Acute intraCerebral Haemorrhage (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Levetiracetam IV CI brief — competitive landscape report
- Levetiracetam IV updates RSS · CI watch RSS
- Ministry of Health and Sports, Myanmar portfolio CI